Insider Selling: Definium Therapeutics (NASDAQ:DFTX) Insider Sells $129,101.01 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 2,867 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider owned 174,633 shares in the company, valued at $7,863,723.99. The trade was a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX opened at $44.95 on Monday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.01. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37. The firm’s 50-day moving average is $24.59 and its 200 day moving average is $19.41.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Research analysts predict that Definium Therapeutics, Inc. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Definium Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after purchasing an additional 3,020 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of Definium Therapeutics in the 4th quarter valued at $117,000. FNY Investment Advisers LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter valued at $107,000. Finally, Caxton Associates LLP purchased a new stake in Definium Therapeutics during the third quarter worth $126,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group set a $60.00 price objective on Definium Therapeutics in a research report on Monday, June 22nd. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Robert W. Baird increased their price objective on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $47.08.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.